SCOPUS 정보 검색 플랫폼

Journal of Clinical Oncology

Volumn 26, Issue 12, 2008, Pages 1924-1925

From silos to a critical path of new agent development: A paradigm to revolutionize clinical research

(1) Benson III, Al B a

a NORTHWESTERN UNIVERSITY (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BEVACIZUMAB; CETUXIMAB; PANITUMUMAB; ANTINEOPLASTIC AGENT;

CANCER RESEARCH; CLINICAL TRIAL; COLON TUMOR; COLORECTAL CANCER; DRUG EFFICACY; EDITORIAL; FOOD AND DRUG ADMINISTRATION; HEALTH CARE; HEALTH CARE PERSONNEL; HUMAN; PRIORITY JOURNAL; ANIMAL; COLORECTAL TUMOR; MEDICAL RESEARCH; METHODOLOGY; NOTE;

ANIMALS; ANTINEOPLASTIC AGENTS; BIOMEDICAL RESEARCH; CLINICAL TRIALS AS TOPIC; COLORECTAL NEOPLASMS; HUMANS;

EID: 42949084222 PISSN: 0732183X EISSN: None Source Type: Journal
DOI: 10.1200/JCO.2007.14.7843 Document Type: Editorial

Times cited : (2)

References (8)

1
- 84871472542
- US Department of Health and Human Services Decision Memo for Clinical Trial Policy CAG-00071R2
- US Department of Health and Human Services Decision Memo for Clinical Trial Policy (CAG-00071R2). http://www.cms.hhs.gov/mcd/viewdecisionmemo .asp?id=210

2
- 42949104050
- Systematic survey of therapeutic trials for metastatic colorectal cancer: Room for improvement in the critical pathway
- Kopetz S, Overman M, Chang D, et al: Systematic survey of therapeutic trials for metastatic colorectal cancer: Room for improvement in the critical pathway. J Clin Oncol 26:2000-2005, 2008
- (2008) J Clin Oncol , vol.26 , pp. 2000-2005
- Kopetz, S.¹ Overman, M.² Chang, D.³

3
- 10644235742
- Food and Drug Administration: Challenge and opportunity on the critical path to new medical products. http://www.fda.gov/oc/initiatives/criticalpath/ whitepaper.pdf
- Challenge and opportunity on the critical path to new medical products

4
- 33746551430
- Food and Drug Administration: Critical path opportunities report, 2006. http://www.fda.gov/oc/initiatives/criticalpath/report/opp_report.pdf
- (2006) Critical path opportunities report

5
- 33750591807
- Invisible barriers to clinical trials: The impact of structural, infrastructural, and procedural barriers to opening oncology clinical trials
- Dilts DM, Sandler AB: Invisible barriers to clinical trials: The impact of structural, infrastructural, and procedural barriers to opening oncology clinical trials. J Clin Oncol 24:4545-4552, 2006
- (2006) J Clin Oncol , vol.24 , pp. 4545-4552
- Dilts, D.M.¹ Sandler, A.B.²

6
- 33750585093
- Processes to activate phase III clinical trials in a cooperative oncology group: The case of Cancer and Leukemia Group B
- Dilts DM, Sandler AB, Baker M, et al: Processes to activate phase III clinical trials in a cooperative oncology group: The case of Cancer and Leukemia Group B. J Clin Oncol 24:4553-4557, 2006
- (2006) J Clin Oncol , vol.24 , pp. 4553-4557
- Dilts, D.M.¹ Sandler, A.B.² Baker, M.³

7
- 15744374441
- Clinical trial designs for predictive marker validation in cancer treatment trials
- Sargent DJ, Conely BA, Allegra C, et al: Clinical trial designs for predictive marker validation in cancer treatment trials. J Clin Oncol 23:2020-2027, 2005
- (2005) J Clin Oncol , vol.23 , pp. 2020-2027
- Sargent, D.J.¹ Conely, B.A.² Allegra, C.³

8
- 26444543829
- Clinical trial designs for prospective validation of biomarkers
- Mandrekar SJ, Grothey A, Goetz MP, et al: Clinical trial designs for prospective validation of biomarkers. Am J Pharmacogenomics 5:317-325, 2005
- (2005) Am J Pharmacogenomics , vol.5 , pp. 317-325
- Mandrekar, S.J.¹ Grothey, A.² Goetz, M.P.³

* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.